Studies have shown that insulin-sensitizing agents, including metformin and PPARγ agonists, are beneficial in preventing kidney damage in both T1DM (120) and T2DM (121) as well as in non-DKD (122). This evidence concerns the gene PPARG and type 2 diabetes mellitus.